Below are the expected dates for Exiqon A/S' annual general meeting and
financial reporting in 2010.

Announcement of full-year results 2009: 5 March 2010
The annual general meeting is scheduled to be held on: 14 April 2010
Interim report for the period 1 January 2010 to 31 March 2010: 19 May 2010
Interim report for the period 1 January 2010 to 30 June 2010: 19 August 2010
Interim report for the period 1 January 2010 to 30 September 2010: 12 November
2010

Additional information:
Lars Kongsbak, CEO, phone +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, phone +45 4566 0888 (cell: +45 4090 2131)

About Exiqon:
Exiqon's products are based on the proprietary LNA™ technology. This
technology offers unique advantages for detection of miRNA biomarkers for life
science researchers, drug developers and cancer treating physicians working
towards personalizing medicine. Exiqon operates in two business areas: Exiqon
Life Sciences has established a position for itself as one of the market's
leading providers of miRNA research products for miRNA analysis in cells.
Research products are used by academia, biotech and pharmaceutical companies
around the world to make groundbreaking discoveries about the correlation
between gene activity and the development of cancer and other diseases. Exiqon
Life Sciences is also collaborating with pharmaceutical companies in their
effort to develop new medicines based on miRNA as biological markers (Exiqon
Pharma Services). Exiqon Diagnostics is developing a series of new molecular
diagnostic products based on miRNA. Exiqon's goal is to gain a market-leading
position for miRNA-based diagnostics. Exiqon is listed on the NASDAQ OMX in
Copenhagen. For more information about us, please visit www.exiqon.com.

Read the full announcement in the attached PDF or at
www.exiqon.com/investor/portal.

announcement_22_2009_financial_calendar_final.pdf